39 results
8-K
EX-1.1
CPRX
Catalyst Pharmaceuticals Inc
5 Jan 24
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
5:23pm
and which relate to the Company’s business.
(xxiii) Environmental Laws. Except as described in the Registration Statement, the General Disclosure … of Hazardous Materials (collectively, “Environmental Laws”), (B) the Company and its subsidiaries have all permits, authorizations and approvals required under
8-K
EX-99.1
CPRX
Catalyst Pharmaceuticals Inc
25 Sep 23
Regulation FD Disclosure
5:46pm
in Q1 23 Completed the seamless U.S. FYCOMPA commercial and MSL team integration in May 2023 Launched Environmental, Social, and Governance “ESG
8-K
EX-10.1
CPRX
Catalyst Pharmaceuticals Inc
23 Jun 23
Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
4:31pm
security, disability, alternative or add-on minimum, customs, excise, stamp, environmental, commercial rent or withholding taxes.
1.129 “Term” has
8-K
EX-99.1
CPRX
Catalyst Pharmaceuticals Inc
10 May 23
Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving
4:47pm
rare neurological assets in alignment with our portfolio expansion strategy.
Launched our inaugural Environmental, Social, and Governance (“ESG
8-K
EX-99.1
jgu dd9r704rq8v
9 Nov 22
Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update
4:32pm
8-K
EX-1.1
qvy2de5 kfen
4 Feb 15
Announces Commencement of Public Offering of Common Stock
12:00am
8-K
EX-1.1
1he3yazbna277qh
3 Apr 14
Announces Commencement of Public Offering of Common Stock
12:00am
8-K
EX-1.1
77fb fnydyzg
29 May 12
Catalyst Pharmaceutical Partners Prices Underwritten Offering
12:00am
424B4
hce32pobixgy
24 May 12
Prospectus supplement with pricing info
12:00am